Cytokine release syndrome (CRS) is a systemic inflammatory reaction caused by widespread activation of immune cells and the release of cytokines, proteins that regulate communication between cells. It is particularly associated with treatments that activate T cells, including chimeric antigen receptor T-cell therapy and certain bispecific antibodies. Clinical manifestations range from fever and fatigue to low blood pressure, impaired oxygenation, and multiple-organ dysfunction. CRS is a clinical syndrome rather than a diagnosis established by a single laboratory test.
Causes and clinical settings
CRS is an important toxicity of several forms of cancer immunotherapy. CAR T cells recognize a target on cancer cells and become activated, while T-cell-engaging bispecific antibodies bring T cells into contact with target cells. Both mechanisms can produce a strong inflammatory response alongside their intended antitumor effects.
Other immune-activating treatments, including some monoclonal antibodies, can also cause CRS. Similar inflammatory reactions occur in certain transplantation settings.
The term cytokine storm is sometimes used interchangeably with CRS, but its meaning is broader and less standardized. It may describe severe systemic inflammation associated with infections, immune disorders, or treatment-related immune activation. Definitions and grading systems developed for immune-effector-cell therapy do not automatically apply to every inflammatory illness with elevated cytokines.
CRS is not simply an allergic reaction. Although both can occur after treatment and cause circulatory or respiratory compromise, their underlying mechanisms differ.
Biological mechanisms
CRS involves an amplifying interaction between activated immune cells, inflammatory mediators, and the lining of blood vessels.
In T-cell-directed therapy, recognition of target cells activates T cells and stimulates cytokine production. These signals recruit and activate additional immune cells, particularly monocytes and macrophages. The resulting inflammatory network includes interleukin-6 (IL-6), interleukin-1, interferon-gamma, and other mediators. Their relative contributions vary with the treatment and clinical setting.
IL-6 has a central role in many treatment-associated cases. It contributes to fever, acute-phase protein production, and vascular changes. However, CRS is not caused by IL-6 alone, and its severity cannot be determined reliably from a single cytokine concentration.
Activation of vascular endothelial cells can increase blood-vessel permeability. Fluid then moves from the circulation into tissues, contributing to edema, reduced circulating volume, and low blood pressure. Inflammatory effects on the lungs, heart, liver, kidneys, and coagulation system may produce additional organ dysfunction.
Clinical manifestations and timing
Fever is usually the earliest recognizable feature. Other early manifestations include chills, fatigue, headache, muscle aches, nausea, and a rapid heart rate. More severe disease may involve:
- Low blood pressure, sometimes requiring medications that support circulation.
- Hypoxia, requiring supplemental oxygen or ventilatory support.
- Capillary leak and fluid accumulation.
- Abnormal liver tests or impaired kidney function.
- Cardiac dysfunction or arrhythmias.
- Abnormalities of blood coagulation.
Onset depends on the treatment. CRS may develop within hours or over several days; some cellular therapies have later onset. Its duration is also variable. Product-specific characteristics, the extent of immune-cell activation, and the amount of target tissue all influence the clinical course.
Neurological changes can accompany treatment-related inflammation, but immune effector cell-associated neurotoxicity syndrome (ICANS) is assessed as a separate toxicity. ICANS may occur during CRS, after CRS has resolved, or without concurrent CRS. Confusion, language disturbance, seizures, and reduced consciousness therefore are not simply incorporated into the CRS severity grade.
Diagnosis and differential diagnosis
Diagnosis rests on the clinical pattern, its timing relative to an immune-activating treatment, and assessment for other explanations. No laboratory finding is sufficiently specific to establish CRS independently.
Evaluation commonly includes a complete blood count, biochemical tests of organ function, coagulation tests, and inflammatory markers. C-reactive protein and ferritin may rise substantially, but these biomarkers are also elevated in infections and other inflammatory conditions. Cytokine assays are not required for routine grading and may not provide results quickly enough to guide acute clinical decisions.
A major challenge is distinguishing CRS from sepsis. Both can cause fever, low blood pressure, hypoxia, and organ dysfunction, and both may occur in the same patient. People receiving cellular therapies may have impaired immune defenses, making infection an especially important competing or coexisting diagnosis.
Other considerations in the differential diagnosis include anaphylaxis, other infusion reactions, cardiopulmonary disease, and metabolic complications of cancer treatment. A separate immune-effector-cell-associated hemophagocytic inflammatory syndrome may also resemble or follow CRS; its recognition requires assessment beyond the CRS grade alone.
Severity grading
The American Society for Transplantation and Cellular Therapy (ASTCT) published a consensus grading system in 2019 to standardize reporting of CRS associated with immune-effector-cell therapies.
At onset, the definition requires a temperature of at least 38°C that is not attributable to another cause. Severity is then determined primarily by hypotension and hypoxia:
| Grade | Principal features |
|---|---|
| 1 | Fever without hypotension or hypoxia attributable to CRS. |
| 2 | Hypotension not requiring vasopressors, and/or hypoxia requiring low-flow nasal oxygen. |
| 3 | Hypotension requiring one vasopressor, with or without vasopressin, and/or hypoxia requiring high-flow nasal oxygen, a facemask, a non-rebreather mask, or a Venturi mask. |
| 4 | Hypotension requiring multiple vasopressors, excluding vasopressin, and/or hypoxia requiring positive-pressure ventilation. |
The more severe of the circulatory or respiratory findings determines the overall grade. Findings must be attributable to CRS rather than another condition. After treatment with antipyretic or anticytokine therapy, fever need not persist for ongoing CRS to be graded.
Other organ toxicities remain clinically important but do not independently determine the ASTCT CRS grade. This grading system also does not identify the cause of an inflammatory illness or replace assessment for infection.
Clinical management
Management combines supportive care, suppression of excessive inflammation when indicated, and evaluation for concurrent complications. The details depend on severity, the triggering therapy, and the treatment protocol.
Supportive measures can include oxygen, carefully managed intravenous fluids, vasopressors, and intensive-care support. Fluid management is complicated by the possibility that low circulating volume and tissue fluid accumulation occur together. Severe respiratory failure may require mechanical ventilation.
Tocilizumab, an antibody that blocks the IL-6 receptor, is an established treatment for severe CAR T-cell-associated CRS and is also used in other treatment-related settings. It does not directly neutralize every cytokine involved in the syndrome. Corticosteroids are used in selected circumstances, including severe, persistent, or protocol-defined CRS and associated neurological toxicity.
Treatment of systemic CRS and treatment of ICANS are not interchangeable. Tocilizumab is not an established treatment for isolated ICANS. Additional anti-inflammatory approaches are used in selected refractory cases, although the evidence and indications vary.
Because infection and CRS can coexist, assessment and treatment of possible infection may proceed alongside anti-inflammatory treatment.
Frequency, risk factors, and prevention
There is no single incidence estimate applicable to all CRS. Reported rates depend on the specific product, disease, dose, patient population, preventive measures, and grading system. Comparisons across studies are especially difficult when different definitions are used.
Greater disease burden, more extensive immune-cell activation, and features of particular treatment products have been associated with higher risk in some settings. These associations do not provide a universally reliable prediction for an individual patient.
Risk-reduction measures used in treatment programs include step-up dosing for certain bispecific antibodies, product-specific premedication, and structured observation after treatment. Such measures reduce risk in some settings but do not eliminate CRS.
Historical development and continuing questions
CRS was recognized as a complication of immune-activating antibody treatments before the development of modern CAR T-cell therapy. The expansion of cellular immunotherapy made standardized recognition and grading increasingly important. IL-6 receptor blockade subsequently became a major component of treatment for severe CAR T-cell-associated CRS.
Continuing research addresses why patients differ in susceptibility, how to distinguish CRS rapidly from infection and related inflammatory syndromes, and how best to control toxicity without compromising antitumor activity. Predictive biomarkers and optimal timing of anti-inflammatory treatment remain context-dependent rather than universally established.